1.Efficacy of Zishen Huoxue Formula in treatment of molecular-targeted therapy-associated proteinuria in patients with primary liver cancer
Jing JING ; Aozhe ZHANG ; Simiao YU ; Xin WANG ; Yongqiang SUN ; Yiling WANG ; Ruixin GAO ; Yinying LU ; Xiaohe XIAO ; Ruilin WANG
Journal of Clinical Hepatology 2026;42(4):874-881
ObjectiveTo investigate the effect of Zishen Huoxue Formula (ZSXHF) on molecular-targeted therapy-associated proteinuria in patients with primary liver cancer (PLC), to assess the efficacy of ZSXHF in the treatment of molecular-targeted therapy-associated proteinuria, and to provide a basis for clinical medication. MethodsA retrospective cohort study was conducted among the PLC patients with molecular-targeted therapy-associated proteinuria who were diagnosed and treated in The Department of Hepatology of Chinese PLA General Hospital, from January 1, 2022 to July 1, 2025. With ZSXHF treatment as the exposure factor, the patients with a cumulative treatment duration of ≥9 weeks were enrolled as traditional Chinese medicine (TCM) group, while those without TCM treatment were enrolled as control group. Propensity score matching was performed for the two groups at a ratio of 1∶1 based on sex, age, 24-hour urinary protein, blood urea nitrogen, and serum creatinine. The independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between groups. Univariate and multivariate Logistic regression analyses were used to investigate the influencing factors for promoting the improvement of targeted-therapy-associated proteinuria. ResultsA total of 137 PLC patients with targeted-therapy-associated proteinuria were enrolled, with 34 patients in the TCM group and 103 in the control group. After follow-up for 6 months, the TCM group had a significant improvement in urinary protein grade compared with the control group (χ2=9.261, P=0.016). There were 25 patients in each group after propensity score matching, and after follow-up for 6 months, there were significant differences between the two groups in urinary protein grade (χ2=15.689, P<0.001) and 24-hour urinary protein (Z=-3.075, P=0.002). After cumulative treatment with ZSXHF for ≥9 weeks, the TCM group had a significantly greater change in 24-hour urinary protein from baseline compared with the control group (t=-2.514, P=0.016), while there were no significant differences in the changes in liver and renal function after ZSXHF intervention between the two groups (all P>0.05). The multivariate Logistic regression analysis showed that ZSXHF treatment (odds ratio=2.901, 95% confidence interval: 1.135 — 7.417, P=0.026) was an independent influencing factor for improvement in molecular-targeted therapy-associated proteinuria. ConclusionZSHXF can effectively alleviate molecular-targeted therapy-associated proteinuria in PLC patients with a favorable safety profile, which provides a new reference for TCM prevention and treatment of molecular-targeted therapy-associated adverse reactions in PLC patients.
2.The Effect of Fuzheng Huaji Formula (扶正化积方) for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma:A Retrospective Cohort Study
Simiao YU ; Jiahui LI ; Jing JING ; Tingting HE ; Yongqiang SUN ; Liping WANG ; Aozhe ZHANG ; Xiaohe XIAO ; Xia DING ; Ruilin WANG
Journal of Traditional Chinese Medicine 2025;66(3):268-274
ObjectiveTo evaluate the clinical efficacy of Fuzheng Huaji Formula (扶正化积方) for chronic hepatitis B to reduce the incidence of liver cirrhosis and hepatocellular carcinoma. MethodsA retrospective cohort study was conducted, collecting medical records of 118 patients with chronic hepatitis B and 234 patients with hepatitis B-related cirrhosis who visited the hospital between January 1, 2014, and December 31, 2018. The use of Fuzheng Huaji Formula was designated as the exposure factor. Patients receiving antiviral treatment for hepatitis B without concurrent Fuzheng Huaji Formula therapy were included in the western medicine group, while those receiving antiviral treatment combined with Fuzheng Huaji Formula for a cumulative treatment lasting longer than 3 months were included in the combined treatment group. The follow-up observation period was five years. Kaplan-Meier survival analysis was used to assess the cumulative incidence of cirrhosis in patients with chronic hepatitis B and the cumulative incidence of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis. Univariate and multivariate Cox regression analyses were employed to examine the factors influencing the occurrence of cirrhosis and hepatocellular carcinoma. ResultsAmong patients with chronic hepatitis B, there were 55 cases in the combined treatment group and 63 cases in the western medicine group; among patients with hepatitis B-related cirrhosis, there were 110 cases in the combined treatment group and 124 cases in the western medicine group. Five-year follow-up outcomes for chronic hepatitis B patients showed that the cumulative incidence of cirrhosis was 5.45% (3/55) in the combined treatment group and 17.46% (11/63) in the western medicine group, with a statistically significant difference between groups (Z = 2.003, P = 0.045). Five-year follow-up outcomes for hepatitis B-related cirrhosis patients showed that the cumulative incidence of hepatocellular carcinoma was 8.18% (9/110) in the combined treatment group and 22.58% (28/124) in the western medicine group, also showing a statistically significant difference (Z = 3.007, P = 0.003). Univariate and multivariate Cox regression analyses indicated that treatment with Fuzheng Huaji Formula is an independent protective factor in preventing the progression of chronic hepatitis B to cirrhosis and the progression of hepatitis B-related cirrhosis to hepatocellular carcinoma (P<0.05). ConclusionCombining Fuzheng Huaji Formula with antiviral therapy for hepatitis B can effectively intervene in the disease progression of chronic hepatitis B, reducing the incidence of cirrhosis and hepatocellular carcinoma.
3.New insights and prospects of drug-induced liver injury in the context of chronic cholestatic liver diseases
Simiao YU ; Jiabo WANG ; Xiaohe XIAO ; Ruilin WANG
Journal of Clinical Hepatology 2025;41(2):365-369
Patients with chronic cholestatic liver diseases face numerous challenges in the detection, assessment, and management of suspected drug-induced liver injury (DILI), and in particular, it is difficult to distinguish cholestatic DILI from the progression of underlying cholestatic liver diseases clinically and histologically. Currently, there is a lack of related research and management guidelines for DILI with chronic cholestatic liver diseases. This article discusses the potential risks, causality, and classification criteria for chronic cholestatic liver diseases with DILI, in order to improve the understanding of such diseases among clinicians and provide a reference for prevention, treatment, and management strategies.
4.Msx2 regulates differentiation of outer enamel epithelial cells by modu-lating cytoskeleton and cell-cell interactions
Zhe YU ; Xiaohe JI ; Jingkun BAI ; Lihui ZHANG ; Juanjuan ZHANG ; Yan SUN ; Limei CHEN ; Xiaoying LIU
Chinese Journal of Pathophysiology 2025;41(3):555-561
AIM:To investigate the mechanism by which muscle segment homeobox 2(Msx2)regulates the differentiation of outer enamel epithelial cells in the enamel organ.METHODS:Tissue paraffin sections were prepared and subjected to hematoxylin-eosin(HE)staining to analyze the effect of Msx2 deficiency on the differentiation status of epithelial cells in the enamel organ at the morphological level.At the ultrastructural level,alterations in cell structure were analyzed.The intermediate steps mediating cell differentiation were identified.Transcriptome sequencing analysis was performed to validate the molecular mechanisms underlying the observed phenomena.RESULTS:Msx2 deficiency was innovatively found to induce severe squamous epithelial hyperplasia in outer enamel epithelial cells of enamel organ,accompanied by dynamic restructuring of the cell cytoskeleton and alterations in cell adhesion at the ultrastructure level.As a transcriptional repressor,the loss of Msx2 expression results in significant increases(P<0.05 or P<0.01)in the mRNA expression levels of integrin β2(Itgβ2),ItgαM,Itgα4,Rac family small GTPase 2(Rac2),Rac/Cdc42 guanine nucleo-tide exchange factor 6(Arhgef6)and protein tyrosine phosphatase receptor type C(Ptprc).CONCLUSION:Msx2 regu-lates cytoskeleton structure and cell-cell interaction through the Rho GTPases signaling pathway,thereby influencing the differentiation state of outer enamel epithelial cells.This study reveals the mechanism through which Msx2 regulates the differentiation of outer enamel epithelial cells,providing a theoretical foundation for the prevention and treatment of enam-el-related clinical dental diseases.
5.Research on the Dimensional Construction,Dynamic Evolution,and Pathway Innovation of Medical-Preventive Integration in County-Level Medical Communities
Chunfeng YUAN ; Yu QIAN ; Xiaohe WANG
Chinese Hospital Management 2025;45(12):17-21
Grounded in the Healthy China strategy,it employs integrated healthcare service theory,collaborative governance theory,and symbiosis theory to systematically analyze the conceptual connotation of medical-preventive integration within county-level medical communities and clarify its seven-dimensional framework of medical-preventive integration.These dimensions encompass resource integration,management integration,information integration,team integration,service integration,assessment integration,and cultural integration.The study delineates its three-phase dynamic evolution characterized by"interaction,coordination,and symbiosis"and outlines future development paths:constructing an intelligent integrated platform,delivering continuous services across the prevention-treatment-rehabilitation continuum,and fostering a multi-stakeholder collaborative governance framework.The findings provide both theoretical foundations and policy recommendations to support the high-quality development of medical-preventive integration in county-level medical communities.
6.Msx2 regulates differentiation of outer enamel epithelial cells by modu-lating cytoskeleton and cell-cell interactions
Zhe YU ; Xiaohe JI ; Jingkun BAI ; Lihui ZHANG ; Juanjuan ZHANG ; Yan SUN ; Limei CHEN ; Xiaoying LIU
Chinese Journal of Pathophysiology 2025;41(3):555-561
AIM:To investigate the mechanism by which muscle segment homeobox 2(Msx2)regulates the differentiation of outer enamel epithelial cells in the enamel organ.METHODS:Tissue paraffin sections were prepared and subjected to hematoxylin-eosin(HE)staining to analyze the effect of Msx2 deficiency on the differentiation status of epithelial cells in the enamel organ at the morphological level.At the ultrastructural level,alterations in cell structure were analyzed.The intermediate steps mediating cell differentiation were identified.Transcriptome sequencing analysis was performed to validate the molecular mechanisms underlying the observed phenomena.RESULTS:Msx2 deficiency was innovatively found to induce severe squamous epithelial hyperplasia in outer enamel epithelial cells of enamel organ,accompanied by dynamic restructuring of the cell cytoskeleton and alterations in cell adhesion at the ultrastructure level.As a transcriptional repressor,the loss of Msx2 expression results in significant increases(P<0.05 or P<0.01)in the mRNA expression levels of integrin β2(Itgβ2),ItgαM,Itgα4,Rac family small GTPase 2(Rac2),Rac/Cdc42 guanine nucleo-tide exchange factor 6(Arhgef6)and protein tyrosine phosphatase receptor type C(Ptprc).CONCLUSION:Msx2 regu-lates cytoskeleton structure and cell-cell interaction through the Rho GTPases signaling pathway,thereby influencing the differentiation state of outer enamel epithelial cells.This study reveals the mechanism through which Msx2 regulates the differentiation of outer enamel epithelial cells,providing a theoretical foundation for the prevention and treatment of enam-el-related clinical dental diseases.
7.Research on the Dimensional Construction,Dynamic Evolution,and Pathway Innovation of Medical-Preventive Integration in County-Level Medical Communities
Chunfeng YUAN ; Yu QIAN ; Xiaohe WANG
Chinese Hospital Management 2025;45(12):17-21
Grounded in the Healthy China strategy,it employs integrated healthcare service theory,collaborative governance theory,and symbiosis theory to systematically analyze the conceptual connotation of medical-preventive integration within county-level medical communities and clarify its seven-dimensional framework of medical-preventive integration.These dimensions encompass resource integration,management integration,information integration,team integration,service integration,assessment integration,and cultural integration.The study delineates its three-phase dynamic evolution characterized by"interaction,coordination,and symbiosis"and outlines future development paths:constructing an intelligent integrated platform,delivering continuous services across the prevention-treatment-rehabilitation continuum,and fostering a multi-stakeholder collaborative governance framework.The findings provide both theoretical foundations and policy recommendations to support the high-quality development of medical-preventive integration in county-level medical communities.
8.Development of a Graded Diagnosis and Treatment System Physician Collaboration Symbiosis Effect As-sessment Questionnaire and Study on Intrinsic Relationships within Dimensions
Yu QIAN ; Xiaohe WANG ; Minzhuo HUANG
Chinese Hospital Management 2024;44(3):27-31
Objective To develop and validate a questionnaire for assessing the synergistic effects of physician col-laboration within a tiered healthcare system,dissect its structural dimensions,and explore the internal logical rela-tionships among these dimensions.Methods Literature review and focus group discussions were employed to clarify the conceptual framework and components of the synergistic effects of physician collaboration in a tiered healthcare system,leading to the development of the questionnaire.Multi-stage sampling was used to survey 1 959 physi-cians.Results The questionnaire for assessing physician collaborative synergy effects consists of four dimensions:col-laborative cognition,collaborative trust,collaborative willingness,and collaborative behavior,comprising 10 items in total.The overall Cronbach's coefficient and the coefficients for four dimensions were all above 0.7.Exploratory factor analysis results extracted four common factors,with a cumulative variance contribution rate of 86.7%.Confirmatory factor analysis revealed that the composite reliability of the four dimensions of the questionnaire was above 0.7,and the average variance extracted was above 0.5.Collaborative cognition influenced collaborative behavior through the chain-mediating roles of collaborative trust and collaborative willingness.Conclusion The developed questionnaire for assessing the synergistic effects of physician collaboration in a tiered healthcare system has good reliability and validity.Its dimensions fit well with the interrelated structure of"knowledge","emotion","intention"and"action",making it a suitable reference tool for evaluating the extent and effectiveness of physician collaboration across different medical institutions within a tiered healthcare system.
9.Effect of Tongxinluo Capsules on Use of Anti-ischemic Drugs in Patients with Chronic Coronary Syndrome of Qi Deficiency and Blood Stasis: A Multicenter, Prospective Cohort Study
Chenhao ZHANG ; Jia WANG ; Yiying LIU ; Xiaohe YANG ; Xuesen WANG ; Meili GAO ; Yu DONG ; Xiaotao LI
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(23):149-156
ObjectiveTo investigate the effect of Tongxinluo capsules on the use of anti-ischemic drugs in patients with chronic coronary syndrome (CCS) of Qi deficiency and blood stasis. MethodA multicenter,prospective cohort study was conducted,with Tongxinluo capsules intervention as the exposure factor. Patients were divided into an exposed group (combination of traditional Chinese and western medicine) and a non-exposed group (western medicine alone),and followed up for one year. The use of anti-ischemic drugs was observed on the day of enrollment and at 3,6,12 months. ResultA total of 186 patients were enrolled,with 128 in the exposed group and 58 in the non-exposed group. There were no statistically significant differences in baseline characteristics between the two groups. At the 3-month follow-up,the types of first-line anti-ischemic drugs used in the exposed group were significantly fewer than those in the non-exposed group (P<0.01),and this difference remained statistically significant at 6 months (P<0.05) but was no longer significant at 12 months. At the 3- and 6-month follow-ups,there were no significant differences between the two groups in the types of second-line anti-ischemic drugs used. However,at the 12-month follow-up,the types of second-line anti-ischemic drugs used in the exposed group were significantly fewer than those in the non-exposed group (P<0.01). At the 3-month follow-up,both groups showed a reduction in the types of first-line anti-ischemic drugs used compared to baseline (P<0.05),with a more pronounced reduction in the exposed group (P<0.05). At the 6-month follow-up,the exposed group showed a significant reduction in the types of second-line anti-ischemic drugs used compared to baseline (P<0.05),while no significant changes were observed in the non-exposed group. At the 12-month follow-up,the difference in the types of second-line anti-ischemic drugs between the exposed and non-exposed groups was statistically significant (P<0.05),while there was no significant difference in the types of first-line anti-ischemic drugs. ConclusionTongxinluo capsules can effectively reduce the use of anti-ischemic drugs in patients with CCS of Qi deficiency and blood stasis.
10.Theoretical exploration and research pathways of the harmonious symbiotic mechanism in the tiered medical treatment system
Xiaohe WANG ; Yu QIAN ; Changling WU ; Jie CHEN ; Xiaoyu CHEN ; Zhiyi PENG
Chinese Journal of Hospital Administration 2023;39(4):269-273
The tiered medical treatment system stands as a cornerstone in the deepening reforms of China′s medical and health sectors, playing a crucial role in building a healthy China. Exploring the harmonious coexistence mechanism of multiple entities on the supply and demand sides of the tiered diagnosis and treatment system, and promoting the formation of a scientific and reasonable tiered diagnosis and treatment order, has become an urgent public proposition that needs to be answered and has significant social impact. Addressing the challenges in China′s tiered medical treatment system, particularly its need for a more systematic, comprehensive, and collaborative approach, this study is informed by a thorough literature review. Based on the harmonious management and symbiosis theories, the authors proposed a theoretical concept and future research path for the formation of a harmonious symbiotic mechanism in the tiered diagnosis and treatment system, in order to pave the way for exploring the harmonious symbiotic mechanism in the tiered diagnosis and treatment system.

Result Analysis
Print
Save
E-mail